We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Microcytosis Is a Risk Marker of Cancer in Primary Care

By LabMedica International staff writers
Posted on 20 May 2020
Microcytosis is a term used to describe red blood cells that are smaller than normal. More...
Anemia is when there are low numbers of properly functioning red blood cells in the body. In microcytic anemia, the body has fewer red blood cells than normal and those red blood cells it does have are also too small.

In anemia of chronic disease, about one-fourth to one-third of these types of anemia are classified as microcytic. Some of the conditions that can cause this type of anemia include: kidney disease, certain cancers, such as Hodgkin's disease, non-Hodgkin's lymphoma, and breast cancer.

A team of medical scientists from the University of Exeter Medical School (Exeter, UK) examined cancer incidence in a cohort of patients with microcytosis, with and without accompanying anemia. The cohort of 12,289 patents were aged ≥40 years using UK primary care electronic patient records. The 1-year cancer incidence was compared between cohorts of patients with a mean red cell volume of <85 femtolitres (fL) (low) or 85–101 fL (normal). Further analyses examined sex, age group, cancer site, and hemoglobin values.

The investigators reported that of 12,289 patients with microcytosis, 497 (4.0%) had a new cancer diagnosis within one year, compared with 1,465 of 73,150 (2.0%), without microcytosis. In males, 298 out of 4,800 with microcytosis were diagnosed with cancer (6.2%) compared with 940 out of 34,653 without (2.7%). In females with microcytosis, 199 out of 7,489 were diagnosed with cancer (2.7%), compared with 525 out of 38 497 without (1.4%). In patients with microcytosis but normal hemoglobin, 86 out of 2,637 males (3.3%), and 101 out of 5,055 females (2.0%) were diagnosed with cancer.

Willie Hamilton, MD, a Professor of Primary Care Diagnostics who oversaw the study, said, “Overall, the risk of cancer in patients with microcytosis was still low, however our study indicates a need to investigate cancer. In two patients with cancer out of three the possibility of cancer is fairly easy to identify. For the other third, symptoms are often vague, and don't clearly point to cancer. For these patients physicians have to use more subtle clues to recognize that cancer may be present. Small red cells have long been recognized with colon cancer, but this study shows that they are a much broader clue, alerting the doctor to the small possibility of one of several possible cancers.”

The authors concluded that microcytosis is a predictor of underlying cancer even if hemoglobin is normal. Although a benign explanation is more likely, clinicians in primary care should consider simple testing for cancer on encountering unexplained microcytosis, particularly in males. The study was published on May 4, 2020 in the British Journal of General Practice.

Related Links:
University of Exeter Medical School


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Online QC Software
Acusera 24•7
New
All-in-One Molecular System
AIO M160
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Originally designed for lung cancer detection and resistance monitoring, the test also shows potential for identifying signals linked to pulmonary fibrosis (image credit: iStock)

Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively

Lung cancer remains difficult to monitor for early progression and treatment resistance, while pulmonary fibrosis continues to pose major challenges for early diagnosis. Clinicians need repeatable, noninvasive... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more

Microbiology

view channel
Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.